- Report
- June 2023
- 840 Pages
Global
From €3453EUR$3,600USD£2,967GBP
- Report
- July 2022
- 600 Pages
Global
From €3166EUR$3,300USD£2,719GBP
- Report
- July 2021
- 155 Pages
Global
From €2638EUR$2,750USD£2,266GBP
€5276EUR$5,500USD£4,532GBP
- Report
- February 2020
- 94 Pages
Global
From €2398EUR$2,500USD£2,060GBP
- Clinical Trials
- September 2018
- 700 Pages
Global
From €2878EUR$3,000USD£2,472GBP
The Prostate Cancer Vaccine is a type of cancer vaccine that is designed to target and destroy cancer cells in the prostate. It works by stimulating the body's immune system to recognize and attack cancer cells. The vaccine is currently in clinical trials and is not yet approved for use in humans.
The Prostate Cancer Vaccine market is a rapidly growing segment of the larger cancer vaccine market. It is expected to benefit from the increasing prevalence of prostate cancer, as well as the development of new technologies and treatments. The market is also expected to benefit from the increasing awareness of the importance of early detection and treatment of prostate cancer.
Some of the companies in the Prostate Cancer Vaccine market include Janssen Pharmaceuticals, Merck, Pfizer, and Sanofi. Show Less Read more
